A Study of Apatinib in Combination With Raltitrexed Treatment in Patients With Advanced Colorectal Cancer
30 patients with advanced colorectal cancer will be enrolled to observe the efficacy and safety of raltitrexed combined with apatinib as a third-line treatment.
Colorectal Cancer
DRUG: raltitrexed combined with apatinib
PFS, Progression-free survival progression-free survival, 6 months
OS, overall survival, 12 months|ORR, Objective Response Rate, 12 months|DCR, Disease Control Rate, 12 months
In this study, we plan to enroll 30 patients with advanced colorectal cancer after failure of second-line standard chemotherapy. The therapeutic regimen is raltitrexed, 3 mg/„é°, ivgtt, d1, apatinib 500 mg, qd,po, d1-21, Every 3 weeks for 1 cycles, the primary end point was PFS, the secondary end point was OS, DCR, ORR etc. Aim to observe the efficacy and safety of raltitrexed combined with apatinib as a third-line treatment of in patients with advanced colorectal cancer.